IP Library Granted Patent US 6,844,436
Granted Patent B2
US 6,844,436 · App. 10/311,397 · Granted Jan 18, 2005

Preparing pyrazolopyrimidinone derivatives for the treatment of impotence

Assignee: Dong A. Pharm. Co., Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,844,436
App. No.
10/311,397
Granted
Jan 18, 2005
Kind
B2
Abstract

A method for preparing pyrazolopyrimidinone derivatives and their pharmaceutically acceptable salts having efficacy on the treatment of impotence, one of male sexual dysfunctions. The method comprises the steps of: a) chlorosulfonating a pyrazolamide compound to obtain a chlorosulfonated compound; b) reacting the chlorosulfonated compound of step (a) with a primary amine to obtain a sulfonamide compound and c) performing an intramolecular cyclization of the sulfonamide compound of step (b) to produce the compound of formula below 1, wherein the steps b) and c) are performed in situ in alcohol by adding a base to the reaction mixture without workup after the step b) is completed.

Claims (23)

1. A method for preparing pyrazolopyrimidinone derivatives of formula 1, as represented in the following scheme 1, comprising the following steps of:

a) chlorosulfonating a pyrazolamide compound of formula 2 to obtain a chlorosulfonated compound of formula 3;

b) reacting the chlorosulfonated compound of formula 3 with a primary amine to obtain a sulfonamide compound of formula 4; and,

c) performing an intramolecular cyclization of the sulfonamide compound of formula 4 to produce the compound of formula 1,

wherein the step b) and c) are performed in situ in alcohol by adding a base to the reaction mixture without workup after the step b) is completed:

wherein R 1 represents hydrogen; C 1 -C 6 alkyl; C 1 -C 3 alkyl fluoride; or C 3 -C 6 cycloalkyl,

R 2 represents hydrogen; substituted or unsubstituted C 2 -C 6 alkyl; C 1 -C 3 alkyl fluoride; or C 3 -C 6 cycloalkyl,

R 3 represents substituted or unsubstituted C 1 -C 6 alkyl; C 1 -C 6 alkyl fluoride; C 3 -C 6 cycloalkyl; C 3 -C 6 alkenyl; or C 3 -C 6 alkynyl, and

R 4 represents substituted or unsubstituted C 1 -C 10 alkyl; substituted or unsubstituted C 1 -C 9 alkenyl; substituted or unsubstituted C 3 -C 6 cycloalkyl; substituted or unsubstituted bezene; or substituted or unsubstituted heterocycle selected from the group consisting of pyridine, isoxazole, thiazole, pyrimidine, indan, benzthiazole, pyrazole, thiadiazol, oxazole, piperidine, morphorine, imidazole, pyrrolidine, thienyl, triazole, pyrrole and furyl,

in which, substituents usable for R 2 , R 3 and R 4 comprises C 1 -C 10 alkyl; C 3 -C 6 cycloalkyl; halogen; C 1 -C 6 alkyl fluoride; C 1 -C 10 alkyloxy; substituted or unsubstituted bezene; or substituted or unsubstituted heterocycle selected from the group consisting of pyridine, isoxazole, thiazole, pyrimidine, indan, benzthiazole, pyrazole, thiadiazole, oxazole, piperidine, morphorine, imidazole, pyrrolidine, thienyl, triazole, pyrrole, and furyl.

2. The method according to claim 1 , wherein

R 1 represents C 1 -C 3 alkyl,

R 2 represents substituted or unsubstituted C 2 -C 6 alkyl,

R 3 represents substituted or unsubstituted C 2 -C 6 alkyl, and

R 4 represents substituted or unsubstituted C 1 -C 6 alkyl, substituted or unsubstituted C 3 -C 6 cycloalkyl, substituted or unsubstituted bezene, substituted or unsubstituted pyridine, or substituted or unsubstituted pyrrole,

in which, substituents usable for R 2 , R 3 and R 4 comprises halogen, substituted or unsubstituted benzene, substituted or unsubstituted heterocycle selected from the group consisting of pyridine, pyrrolidine, piperidine, pyrrole, and substituted or unsubstituted C 3 -C 6 cycloalkyl.

3. The method according to claim 1 , wherein said derivative of formula 1 is selected from the group consisting of 5-[2-propoxy-5-(1-methyl-2-pyrrolidinylethyl amidosulfonyl)phenyl]-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo(4,3-d)pyrimidin-7-one, 5-[2-propoxy-5-(1-methyl-3-pyrrolidinylmethyl amidosulfonyl) phenyl]-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo(4,3-d)pyrimidin-7-one, and 5-[2-propoxy-5-(2-pyridylmethyl amidosulfonyl)phenyl]-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo(4,3-d)pyrimidin-7-one.

4. The method according to claim 1 , wherein said step a) is carried out at about 20° C. or lower.

5. The method according to claim 1 , wherein said step b) is carried out at about 20° C. or lower.

6. The method according to claim 1 , wherein said alcohol is ethanol.

7. The method according to claim 1 , wherein the said c) is performed in the presence of a base selected from the group consisting of metal salts of alcohols, metal salts of ammonia, amines, alkali or alkali earth metal hydrides, hydroxides, carbonates, bicarbonates, an bicyclic amidines such as DBU (1,8-diazabicyclo[5.4.0]undec-7-ene) and DBN (1,5-diazabicyclo[4.3.0.]non-5-ene).

8. A method for preparing salts of pyrazolopyrimidinone derivatives of formula 1 by reacting pyrazolopyrimidinone compounds obtained by the method of claim 1 with a free acid.

9. The method according to claim 8 , wherein said free acid is selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, posphoric acid, citric acid, acetic acid, lactic acid, tartaric acid, maleic acid, fumaric acid, gluconic acid, methanesulfonic acid, glycolic acid, succinic acid, p-toluenesulfonic acid, galacturonic acid, embonic acid, glutamic acid and aspartic acid.

Assignments (3)
CHANGE OF NAME Recorded Jul 22, 2013
From: DONG-A PHARMTECH CO., LTD.
To: MEZZION PHARMA CO., LTD.
Reel/Frame 030849/0081 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 11, 2009
From: DONG-A PHARM. CO., LTD.
To: DONG-A PHARMTECH CO., LTD.
Reel/Frame 023075/0323 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 11, 2002
From: YOO, MOO-HI; KIM, WON-BAE; CHANG, MIN-SUN; KIM, SOON-HOE; KIM, DONG-SUNG; BAE, CHUL-JUN; KIM, YONG-DUCK; KIM, EUN-HA
To: DONG A PHARM. CO., LTD.
Reel/Frame 014019/0972 →
Priority Claims (1)
KR 2000-34966 · Jun 23, 2000 · national
Continuity (1)
Related Publication 20030176696A1 · Sep 18, 2003